Insulin resistance pathway modulation

"Insulin resistance pathway modulation" describes therapeutic strategies aimed at altering one or more molecular mechanisms underlying impaired cellular response to insulin. Rather than being a single molecule or protein target, it encompasses interventions directed at various nodes within the complex network regulating glucose uptake and metabolism—such as enhancing activity of the insulin receptor itself; modulating downstream effectors like IRS proteins; activating nuclear receptors such as PPARs; inhibiting enzymes involved in lipid synthesis like acetyl-CoA carboxylase; or improving glymphatic clearance relevant for neurodegeneration. Because many distinct molecules contribute to these processes—including kinases, phosphatases (e.g., PTP1B), adapter proteins (CAP/Cbl), transcription factors (MondoA/ChREBP), and others—therapeutic approaches are highly varied depending on which aspect of pathophysiology they address.[1][2][3][4]

Other names

Insulin signaling pathway modulationModulation of insulin sensitivityInsulin sensitization pathways

Drugs may enhance insulin receptor signaling, increase glucose uptake via GLUT4 translocation, activate PPARs to improve lipid/glucose metabolism, or inhibit enzymes like ACC or DGAT2 involved in lipid synthesis/metabolism.